BSE · 538964
Mercury Laboratories Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹76 Cr with net profit ₹3 Cr — a 4.13% net margin, versus 7.38% the period before.
Shareholding
As of 2026-06-30
- Promoter73.66%
- Public26.34%
1,328 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.57× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #29 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 84.67 | 22.07 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,167 Cr | 326.41 | 19.57 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.5 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
| Mercury Laboratories Limited(this company) | ₹94 Cr | 21.49 | 1.62 | 8.32% | 5.65% |
AI analysis
AI-generated · google/gemini-2.5-flashMercury Laboratories Limited is listed with a market capitalization of Rs 103 Cr. The company reported revenue of Rs 76.17 Cr and a profit margin of 6.37%. Its book value per share is Rs 484, and earnings per share (EPS) are Rs 42.68. The stock's 52-week high is Rs 976 and its 52-week low is Rs 620.55.
Positives
- +The promoter holding is high at 73.6583% as of June 30, 2026.
- +The debt-to-equity ratio is low at 0.11.
- +The company has a high dividend yield of 41%.
Negatives
- −Revenue decreased by 0.62% from Rs 76.6475 Cr in March 2024 to Rs 76.1699 Cr in March 2025.
- −Net profit decreased by 44.48% from Rs 5.6542 Cr in March 2024 to Rs 3.1449 Cr in March 2025.
- −EPS declined by 44.48% from Rs 47.12 in March 2024 to Rs 26.21 in March 2025.
- −The company has not disclosed quarterly results since March 2026.
Financial Performance
In the fiscal year ending March 2025, Mercury Laboratories Limited reported revenue of Rs 76.1699 Cr, a slight decrease from Rs 76.6475 Cr in March 2024. Net profit for March 2025 was Rs 3.1449 Cr, which is lower than the Rs 5.6542 Cr reported in March 2024. Earnings per share (EPS) also decreased to Rs 26.21 in March 2025 from Rs 47.12 in March 2024.
Profitability & Returns
The company's profit margin stood at 6.37%. Return on equity (ROE) was 8.32%, and return on capital employed (ROCE) was 10.7538%. The EPS in the last reported annual period was Rs 42.68. EBITDA for the fiscal year ending March 2025 was Rs 5.2094 Cr, a decline from Rs 7.3033 Cr in March 2024.
Balance Sheet
Mercury Laboratories Limited has a debt-to-equity ratio of 0.11. The book value per share is Rs 484. The dividend yield for the company was 41%. No information regarding overall assets or liabilities was provided.
Ownership & Pledges
As of June 30, 2026, promoters held 73.6583% of the company's shares. Public shareholding was 26.3417%. There was no reported FII or DII holding. The number of shareholders was 1328. There were no reported promoter pledges.
Regulatory & Surveillance
Mercury Laboratories Limited is not currently under any regulatory observation or surveillance framework.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Mercury Laboratories Limitedshare price & fundamentals